Document is current
Any future updates will be listed below
-
Authors
Cigler, Marko https://orcid.org/0000-0003-1861-7968
Imrichova, Hana https://orcid.org/0000-0003-0385-1823
Frommelt, Fabian https://orcid.org/0000-0003-3666-8005
Caramelle, Lucie
Depta, Laura
Rukavina, Andrea https://orcid.org/0000-0001-8254-9360
Kagiou, Chrysanthi https://orcid.org/0000-0002-2795-1194
Hannich, J. Thomas https://orcid.org/0000-0002-2286-4956
Mayor-Ruiz, Cristina https://orcid.org/0000-0001-6442-5495
Superti-Furga, Giulio https://orcid.org/0000-0002-0570-1768
Sievers, Sonja https://orcid.org/0000-0003-0854-4507
Forrester, Alison https://orcid.org/0000-0003-3352-9173
Laraia, Luca https://orcid.org/0000-0001-6692-3412
Waldmann, Herbert https://orcid.org/0000-0002-9606-7247
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
- License Information
-
More Information
Article History
Received: 27 March 2023
Accepted: 10 April 2024
First Online: 21 June 2024
Competing interests
: G.E.W. and G.S.-F. are scientific founders and shareholders of Proxygen and Solgate. G.E.W. is on the Scientific Advisory Board of Nexo Therapeutics. The laboratories of G.E.W. and G.S.-F. received research funding from Pfizer. C.M.-R. is part of the Scientific Advisory Board of Nostrum Biodiscovery. The C.M.-R. lab receives research funding from Aelin Therapeutics and Almirall. The remaining authors declare no competing interests.
